Amgen Inc

Amgen’s stock rises as breakthrough CRISPR‑CAR‑T for pancreatic cancer and an ADC for CKD gain FDA designations, promising new revenue streams and investor confidence.

Amgen’s stock rebounds as analyst upgrades and a robust therapy pipeline—including CAR‑T and kinase inhibitors—boost investor confidence and signal strong growth prospects.

Amgen’s steady share price, backed by solid earnings and promising biotech pipeline, shows potential upside as Phase 3 data for AMG 301, AMG 701, and AMG 510 emerge.

Amgen’s latest investor activity shows institutional confidence amid a downgrade, highlighting pipeline strengths, pricing pressures and patent risks.

Amgen’s $840 m purchase of Dark Blue Therapeutics adds a promising small‑molecule AML candidate to its pipeline, positioning the company for premium pricing, patent protection, and a 4‑5‑year market launch in the $4.3 bn AML space.

Amgen’s modest Fitch upgrade reflects solid debt ratios and new U.S. government partnership, yet rising biosimilar competition could pressure margins and spark strategic shifts in pricing, production, and diagnostics.

Amgen partners with the U.S. government to curb drug prices, aligning Medicare/Medicaid rates while keeping innovative biologics affordable.

Amgen joins a multi‑pharma pact to cut U.S. drug prices, gaining tariff exemption and boosting margins while lowering costs for cash payers and Medicaid.

Amgen raises its dividend to 2.68%—a move that boosts income appeal but hinges on patent cliffs, AI‑driven R&D, and ESG strategy for long‑term growth.

Amgen’s new $2.38 dividend and breakthrough VESALIUS‑CV results boost its 32 % PCSK9 share, positioning it for growth in a $452 B cardiovascular‑metabolic market.